# Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

> **NCT05050318** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 90 (actual)

## Conditions studied

- Influenza Immunization
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation
- **BIOLOGICAL:** Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation

## Key facts

- **NCT ID:** NCT05050318
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-08
- **Primary completion:** 2021-11-10
- **Final completion:** 2021-11-10
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050318, "Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05050318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*